Bendamustine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Bendamustine: alkylating agent → mantle cell lymphoma
One-Sentence Summary
Bendamustine is a bifunctional alkylating cytotoxic agent with activity across mature B-cell malignancies. The TxGNN model predicts it may be effective for mantle cell lymphoma, with 40 clinical trials and 20 publications compiled for this prediction, including several completed Phase 3 randomised trials of bendamustine-rituximab.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | mantle cell lymphoma |
| TxGNN Prediction Score | 0.9963 |
| Evidence Level | L1 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Bendamustine is an alkylating agent with a purine-analogue-like structure. It produces DNA cross-links and strand breaks. Detailed mechanism of action data are not otherwise available in the data compiled for this report.
Mantle cell lymphoma is a mature B-cell neoplasm, closely related to other B-cell lymphomas in which bendamustine is used. Bendamustine plus rituximab (BR) is an established backbone in mantle cell lymphoma, and Bruton tyrosine kinase (BTK) inhibitors are now being added to it in large randomised trials. This supports the plausibility of the TxGNN prediction.
Clinical Trial Evidence
Selected trials most relevant to mantle cell lymphoma (the full compiled set is larger):
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00991211 | Phase 3 | Completed | 549 | First-line BR versus R-CHOP in advanced indolent lymphoma and mantle cell lymphoma (non-inferiority on progression-free survival) |
| NCT00877006 | Phase 3 | Completed | 447 | BRIGHT: BR versus R-CVP/R-CHOP in indolent NHL or mantle cell lymphoma |
| NCT01776840 | Phase 3 | Completed | 523 | Ibrutinib added to BR in newly diagnosed mantle cell lymphoma, age 65 or older |
| NCT02972840 | Phase 3 | Active, not recruiting | 635 | Acalabrutinib plus BR versus placebo plus BR in untreated mantle cell lymphoma |
| NCT06363994 | Phase 3 | Recruiting | 476 | Orelabrutinib plus BR versus BR in treatment-naive mantle cell lymphoma |
| NCT06084936 | Phase 3 | Recruiting | 182 | Glofitamab versus investigator’s choice (BR or R-Len) in relapsed/refractory mantle cell lymphoma |
| NCT00891839 | Phase 2 | Completed | 45 | BR in relapsed/refractory mantle cell lymphoma |
| NCT01412879 | Phase 2 | Completed | 53 | R-HCVAD/MTX/ARA-C versus R-bendamustine induction before autologous transplant in untreated mantle cell lymphoma |
| NCT04115631 | Phase 2 | Active, not recruiting | 360 | BR with or without high-dose cytarabine and acalabrutinib in untreated mantle cell lymphoma |
| NCT03834688 | Phase 2 | Completed | 33 | BR plus venetoclax in untreated mantle cell lymphoma over 60 years |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23433739 | 2013 | RCT | Lancet | BR versus R-CHOP first-line in indolent and mantle cell lymphomas (phase 3 non-inferiority) |
| 24591201 | 2014 | RCT | Blood | BRIGHT study: BR versus R-CHOP/R-CVP in indolent NHL or mantle cell lymphoma |
| 30811293 | 2019 | Cohort | J Clin Oncol | BRIGHT 5-year follow-up |
| 35657079 | 2022 | RCT | N Engl J Med | Ibrutinib plus BR in untreated mantle cell lymphoma |
| 40311141 | 2025 | RCT | J Clin Oncol | Acalabrutinib plus BR in untreated mantle cell lymphoma |
| 41052510 | 2025 | RCT | Lancet | ENRICH: ibrutinib-rituximab versus immunochemotherapy (R-CHOP or BR) in untreated mantle cell lymphoma, age 60 or older |
| 41132246 | 2025 | Guideline | HemaSphere | EHA-EU MCL network guidelines for diagnosis and treatment |
| 40975105 | 2025 | Phase 2 | Lancet Haematol | Rituximab, bendamustine, cytarabine then venetoclax in older high-risk mantle cell lymphoma |
| 32126141 | 2020 | Phase 2 | Blood Adv | Rituximab-bendamustine then rituximab-cytarabine induction in transplant-eligible mantle cell lymphoma |
| 26755518 | 2016 | Review | J Clin Oncol | Mantle cell lymphoma review, noting benefits of maintenance rituximab and bendamustine in older patients |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10760H | Bendamustine Sandoz | Powder for injection containing bendamustine hydrochloride 100 mg | Not recorded in the local data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent) |
| Myelosuppression Risk | High (neutropenia, thrombocytopenia and anaemia are listed as concerns in the compiled data) |
| Emetogenicity Classification | Please refer to the Product Information (PI) |
| Monitoring Items | Full blood count with differential, liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Conditions of concern (relations recorded in the compiled safety data, not label text): liver failure, kidney disease, liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, anaemia, macrocytic anaemia, pyoureter.
- Drug Interactions: 100 interactions were found. Major-level interactions include deferiprone and samarium (153Sm) lexidronam (both add to myelosuppression risk). Moderate-level interactions include omeprazole, esomeprazole, cimetidine, caffeine, mercaptopurine, ticlopidine, chloramphenicol, deferasirox, roflumilast and osilodrostat, among others.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several completed Phase 3 randomised trials and multiple publications directly study bendamustine-rituximab in mantle cell lymphoma, including first-line comparisons and BTK-inhibitor combinations, giving strong evidence. Safety data in the compiled material are limited and bendamustine carries significant myelosuppression risk.
To proceed, the following is needed:
- TGA Product Information review (warnings, contraindications, approved indications) for Bendamustine Sandoz
- Confirmation of the mantle cell lymphoma subgroup results in mixed-lymphoma trials (e.g. NCT00991211, NCT00877006)
- Detailed mechanism of action data
- A haematological and infection monitoring plan, with dose adjustment in hepatic and renal impairment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.